ENTA vs PFE
ENTA: Enanta Pharmaceuticals is a clinical-stage biotechnology company developing oral, small-molecule therapies for RSV and immunological diseases, supported by ongoing hepatitis C royalty revenues. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | ENTA | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $12.10 | $27.82 | |
| Market cap | $352M | $158.6B | |
| P/E as of 2026-10-08 | n/a | 36.83 | |
| Net margin FY2025, SEC XBRL | -125.4% | +12.4% | PFE higher |
| Operating margin FY2025, SEC XBRL | -130.7% | n/a | |
| ROE FY2025, SEC XBRL | -126.5% | +9.0% | PFE higher |
| ROA FY2025, SEC XBRL | -29.2% | +3.7% | PFE higher |
| Debt / equity as of 2026-09-03 | 1.25 | 0.74 | PFE lower |
| Revenue growth (YoY) as of 2026-09-03 | +0.7% | -0.2% | ENTA higher |
| Revenue CAGR (3y) SEC XBRL | -8.8% | -14.8% | ENTA higher |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 11 | PFE higher |
| Beta as of 2026-09-03 | 0.87 | 0.39 | |
| 1-year return as of 2026-10-08 close | +7.1% | +8.3% | PFE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.